CRH NYSE
CRH plc

What happened
-5.72% 2026-03-05

From 2026-03-05 session.

Three-week slide accelerates as materials sector buckles under broad risk-off pressure

CRH reported full year 2025 results on February 18, 2026, showing net income of 3.8 billion dollars, up 8 percent year-over-year, and adjusted EBITDA of 7.7 billion dollars, up 11 percent. Total revenues reached 37.4 billion dollars, up 5 percent. The company declared a quarterly dividend of 0.39 dollars per share, up 5 percent year-over-year, and commenced a new 0.3 billion dollar quarterly share buyback program.

Full analysis covers our editorial take, sources, and more.

Track CRH — big moves explained

What happened. Why it matters. 30 seconds.

CRH explained

What does CRH plc do?

CRH is the world's largest building materials company, producing cement, aggregite, asphalt, and readymixed concrete across North America and Europe, with $37.4 billion in 2025 revenue. Added to the S&P 500 index, the company has positioned itself as a key beneficiary of U.S. infrastructure spending. Despite record financial results and positive 2026 guidance, the stock has been caught in a sharp cyclical sector rotation away from materials and industrial names.

How does WTF Just Happened track CRH plc?

We watch CRH for moves that stand out from normal trading -- the kind of day that makes you ask "WTF just happened?" When CRH plc moves beyond its usual range, our AI digs through 15-20 news sources to piece together what drove it. No predictions, no trading advice -- just a clear explanation in about 30 seconds.

See what else moved today →

What a WTF analysis looks like

From a recent analysis

The near-zero move marks the first session without meaningful downside since the CagriSema trial results triggered a 16% single-day collapse on Monday. The cumulative decline over five sessions exceeds 20%, and today's stabilization — particularly against a weak broader market tape — suggests the acute phase of post-trial repositioning has run its course. the stock is underperforming pharma peers by about 0.8 percentage points, a far narrower gap than the 2-3 point divergences seen earlier in the week, indicating the stock-specific pressure is fading. No fresh catalysts have emerged since Tuesday's U.S. price-cut announcement and JP Morgan downgrade. The Kepler Capital Markets downgrade to Hold reported Wednesday is reactive to the prior week's events rather than a new development. Consensus now sits at Hold with an average price target of $56.07, roughly 49% above current levels — a wide gap that reflects deep uncertainty about Novo's competitive trajectory rather than conviction in near-term upside.
Get analysis like this for CRH